M. Aslaner Et Al. , "The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data," CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , 2023
Aslaner, M. Et Al. 2023. The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA .
Aslaner, M., GEDÜK, A., Acar, I. H., POLAT, M. G., Sunu, C., BOLAMAN, A. Z., ... Hacibekiroglu, T.(2023). The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA .
Aslaner, Muzeyyen Et Al. "The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data," CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , 2023
Aslaner, Muzeyyen Et Al. "The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , 2023
Aslaner, M. Et Al. (2023) . "The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA .
@article{article, author={Muzeyyen Aslaner Et Al. }, title={The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data}, journal={CLINICAL LYMPHOMA MYELOMA & LEUKEMIA}, year=2023}